ARTICLE | Company News
Debiopharm S.A., Curis, Mercury Therapeutics deal
August 10, 2009 7:00 AM UTC
Debiopharm added to its preclinical programs this week with two deals. Curis granted Debiopharm an exclusive, worldwide license to develop and commercialize its heat shock protein 90 (Hsp90) technology, which includes CUDC-305 and back-up compounds. CUDC-305 is in preclinical testing to treat cancer, with Phase I testing expected to begin this half. Curis will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. ...